This application claims priority of Netherlands Application NL 1026323, filed on Jun. 3, 2004, the contents of which are expressly incorporated herein by reference in their entirety including the contents and teachings of any references contained therein.
This invention relates to devices for storing and manipulating a radiation source, comprising a safe for storing at least one capsule comprising a radioactive material, a transport element for moving the capsule through a transport tube connected to the safe and leading to an applicator, and a drive mechanism for driving the transport element.
With such devices, through the drive mechanism, for instance a transport wire wound onto a reel and connected with the capsule, a source can be brought to an applicator and halted or moved at one or more sites to locally apply concentrated radiation in the body of a patient. Such devices are known and comprise a radioactive source of the isotope Cobalt 60, Cesium 187 or Iridium 192, which can be generally designated as “strong radiators.”
Such isotopes require a highly shielded, 30-75 cm concrete treatment chamber to protect hospital personnel and other attendants.
The invention comprises a device with an isotope having a considerably lower emitted radiation energy, thereby allowing work to be done in standard treatment rooms or standard operating rooms with a shielding of about 25 cm concrete at most.
This is achieved, according to the invention, by the use of the features of the claimed invention. A lower energy radiation source is used which has as an advantage that the shielding measures are considerably less stringent because of the lesser penetrative power of the lower energy radiator. By enriching the low energy radiation source, a higher dose rate can be delivered and can shorten a treatment without the radiation source unduly increasing in volume. It is noted that in itself the low energy radiation source as an application is known in the treatment of tumors, but the intensity of these radiators is too low to use a so called high dose rate treatment (HDR treatment), whereby a tumor is exposed for a relatively short time to a high radiation intensity. In view of the specific use of the device, the known low energy radiators would necessitate an unduly long radiation time to deliver a sufficient dose.
Preferably, therefore, an isotope is used having a relatively lower energy with respect to the above-mentioned sources, such as Ytterbium-169, Iodine-125, Palladium-103, or Thulium-170 or Tungsten-181. According to the invention, these sources are enriched to a sufficient concentration to obtain sufficiently specific activity in a small capsule. This can be done, for instance, through an ultracentrifuge process.
In an embodiment, the source has been enriched such that a delivered dose rate comes to lie in the HDR range. This range is defined in the so-called ICRU reports (ICRU-38 en ICRU-58). In a specific embodiment, the source is enriched such that a dose rate is at least 12 Gray/hour in a clinical specification spot, for instance at a distance of about 1 cm from the source.
In an embodiment, the source comprises Palladium-103. The weight percentage of Palladium-103 is then at least 3%. In another embodiment, the source comprises Iodine-125, in a weight percentage of at least 15%. In a further embodiment, the source comprises Ytterbium-169, in a weight percentage of Ytterbium-169 of at least 0.5%. In another embodiment, the source comprises Tungsten-181 that is enriched to a weight percentage of at least 5%.
The capsule in an exemplary embodiment has a diameter of at most 5 mm and a length of at most 50 mm.
The appended claims set forth the features of the present invention with particularity. The invention, together with its objects and advantages, may be best understood from the following detailed description taken in conjunction with the accompanying drawings of which:
In
To achieve a desired absorption level, the table shows that for Palladium-103, with a dose rate of 29 GBq/cm, a weight percentage of 4.5% is desired. Likewise, it has been found that for Iodine-125 (135 GBq/mm) a minimum weight percentage of 21% is desired, and for Ytterbium-169 (37.5 GBq/mm) a weight percentage of 2.5%. Finally, for Iridium-192 a desired weight percentage of 1% has been found.
The invention is not limited to the isotopes mentioned in the specification. It is also possible to use other isotopes of a sufficiently low energy, so that they can easily be shielded and they achieve a sufficiently high specific activity to fit into a small capsule. Such sources are understood to fall within the scope of the claims as defined in the following.
Number | Date | Country | Kind |
---|---|---|---|
1026323 | Jun 2004 | NL | national |